Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
Frontiers | A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine ...
BPN14770 | PDE4D inhibitor | 1606974-33-7 | AdooQ®
BPN14770 CAS#: 1606974-33-7
(PDF) A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine-Induced ...
Exploratory biomarkers showing the numerical superiority of BPN14770 ...
BPN14770 Improved Behavioral Phenotypes of fmr1 KO Mice (A) Wild-type ...
| Proteomics analysis flow chart of BPN14770 treatment in humanized ...
BPN14770 Structure – Dan's Drug Blog
BPN14770 differentiated the high affinity binding site in humanized ...
Tetra Announces $40M to Advance BPN14770 for FXS and Alzheimer's ...
Memory drug BPN14770 moves into Phase 1 safety trial
Effect of BPN14770 on Dendritic Spine Length. The distribution of spine ...
BPN14770 Shows Cognition Benefits in Fragile X Phase 2 Clinical Trial
Tetra Therapeutics Shares Their BPN14770 Trials | NFXF
| The effects of BPN14770 on aversive memory of Scopolamine treated ...
BPN14770 for Fragile X Syndrome Clinical Trial 2024 | Power
BPN14770 drug: innovative treatment for cognitive function in adult ...
Clinical Trials: Phase 2B/3 Studies of BPN14770 in Fragile X Syndrome ...
Positive Phase II Study of BPN14770 in patients with Fragile X syndrom ...
BPN14770 POWDER (1 GRAM) – UMBRELLA Labs
| The effects of BPN14770 on spatial learning and memory of Scopolamine ...
New Preclinical Research Suggests Tetra Therapeutics’ BPN14770 Protects ...
Clinical Trials: Phase 2B/3 Studies of BPN14770 in Fragile X syndrome ...
Zatolmilast (BPN14770) | PDE4D Inhibitor | MedChemExpress
Zatolmilast (BPN14770) | PDE inhibitor | CAS 1606974-33-7 | Selleck
Zatolmilast | PDE | TargetMol
RCSB PDB - 6NJJ: Crystal Structure of the PDE4D Catalytic Domain and ...
Memory enhancing effects of BPN14770, an allosteric inhibitor of ...
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D ...
(PDF) Memory enhancing effects of BPN14770, an allosteric inhibitor of ...
Nat Med：BPN14770改善脆性X综合征（FXS）患者的认知能力-MedSci.cn
Schematic Diagram Depicting Treatment Groups and Schedule of Events ...
阿爾茲海默症治療的新希望：BPN14770已進入臨床實驗！ - 每日頭條
Targeting PDE4D, EGFR or PARP1 using clinically tested or approved ...
Schematic of phosphodiesterase 4D7 (PDE4D7)-based mechanotransduction ...
Selective PDE4D inhibitor shows potential to treat Fragile X syndrome
PDE4D mediates SOC resistance and inhibiting PDE4D induces BRCAness ...
Subject demographics and baseline characteristics for the treatment ...
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
NCATS Enables IND Clearances and Drug Approvals | National Center for ...
Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET ...
PDE4D: A Multipurpose Pharmacological Target
Discovery, Radiolabeling, and Evaluation of Subtype-Selective ...
MK-777 ACETAMOREN SARM POWDER (60 CAPSULES) (10MG/CAPSULE, 600MG TOTAL ...
LS mean change from baseline values through week 24 for the NIH-TCB and ...
A switch from ER to EGFR dependence characterizes SOC resistance ...
(PDF) Auditory N1 event-related potential amplitude is predictive of ...
Inhibition of the upregulated phosphodiesterase 4D isoforms improves ...
Auditory N1 event-related potential amplitude is predictive of serum ...
Chemical structure of phosphodiesterase 4 (PDE4) inhibitor GPD-1116 is ...
Discovery of Subtype Selective Phosphodiesterase-4D (PDE4D) Ligands and ...
Review on anti-alzheimer drug development: approaches, challenges and ...
Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with ...
Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a ...
PharmaShots Interview: Tetra Therapeutics' Mark Gurney Shares Insight ...
4[2(3-氯苯基-6(三氟甲基-4-吡啶基]甲基-苯乙酸，BPN14770，1606974-33-7-升德医药
Tetra Discovery Partners Research Supports Ability of Novel Selective ...
IBMX (3-Isobutyl-1-methylxanthine) | ≥99%(HPLC) | Selleck | PDE 阻害剤
塩野義製薬、認知機能改善薬候補の第2相臨床試験を実施 | 認知症ねっと
Emerging autism and Fragile X syndrome treatments: Trends in ...
PDE4B/7A-IN-1 | Phosphodiesterase Inhibitor | MedChemExpress
시오노기, PDE4D 약물 개발 '테트라' 지분 50% 확보 - 바이오스펙테이터
#bpn14770 #innovation #biotech #bpn14770 #eonbiotech #peptidesynthesis ...
Frontiers | Recent developments of phosphodiesterase inhibitors ...
FRAXA Research Foundation | The scope of research on zatolmilast ...
BPN14770, 취약 X 증후군 환자의 인지 기능을 측정한 첫 약물 연구 - 레어노트
Phosphodiesterase 4 inhibition as a novel treatment for stroke [PeerJ]
phosphodiesterase 4D | Phosphodiesterases, 3',5'-cyclic nucleotide ...
PDE4D: A Multipurpose Pharmacological Target - PMC
Recent developments of phosphodiesterase inhibitors: Clinical trials ...
Dendritic Spine Multi-Dimensional Feature Distribution Plots ...
